Johnson & Johnson: latest news - GoINPHARMA
Wednesday, 19 September 2018 - 10:22

Johnson & Johnson

Johnson & Johnson receives $2.1bn offer for Lifescan

Johnson & Johnson has announced today after trading had closed that it had received an acquisition offer by private equity Platinum Equity for Lifescan products. Lifescan is the leading brand in the blood sugar meters and Platinum Equity has valued…

Fortive offers $2.8bn for Johnson & Johnson’s ASP unit

US-based Johnson & Johnson has announced that the industrial Fortive Corp Group has submitted a $2.8bn bid–all in cash–to acquire  Advanced Sterilization Products (ASP) unit, which produces solutions to prevent infections in hospitals and other health units. ASP generated sales…

Positive first quarter for Johnson & Johnson

US-based pharmaceutical giant Johnson & Johnson has reported today, before Wall Street opened, its first-quarter results, which are beyond analyst’s expectations. Revenues in 2017 reached $20bn and profits were $2.06bn, whereas analysts expected, respectively, $19.5bn and $2.0bn. The good performance…

Chinese biotech sector, leader in CAR-T technology

China has clearly acquired an outstanding position in the CAR-T area, with 116 ongoing clinical trials, versus 96 in the US and 15 in Europe. Chinese researchers are obtaining positive results in the treatment of blood cancers considered incurable before…

Verb Surgical, Google’s latest gamble in healthcare

Verb Surgical is a young California-based startup established in 2015, which has recently attracted media as it has raised $500m in funding, its two main funders being Alphabet (Google) and Johnson & Johnson. Verb develops surgical robots costing up to…

First offer ($2.1bn) for J&J’s LifeScan

Platinum Equity, a private equity with $ 13 billion of assets, has submitted a $2.1bn offer to the US-based group Johnson & Johnson  for its LifeScan arm, focused on the diabetes area. The LifeScan unit, headquartered in Chesterbrook (Pennsylvania) and…

Johnson and Johnson exploring sale of ASP ($2bn)

Johnson & Johnson is reportedly weighing a sale of its subsidiary ASP, which manufactures products for sterilizing and disinfecting medical tools. According to analysts, the divestiture is likely to fetch the pharma giant at least $2bn. The deadline to submit…

Johnson & Johnson’s Erleada approved for prostate cancer treatment

Johnson & Johnson has obtained the FDA approval for Erleada (apalutamide) in patients with non-metastatic 
prostate cancer, developing despite hormonal therapy. In fact, Erleada is the first treatment approved for this cancer type. Erleada enters into direct competition with Xtandi…

Excellent momentum of Idorsia continues, shares rise

The Swiss biotech Idorsia keeps surprising analysts and investors with excellent financial performances and strategic decisions. Its shares have increased by over 34% over the last three months, taking its capitalization to CHF2.76bn. Moreover, Idorsia before Christmas entered into a…

JnJ secures rights to Idorsia’s hypertension therapy ($160m)

Switzerland-based biotech group Idorsia, established as JnJ acquired Actelion, has announced that Janssen–a subsidiary of JnJ’s–has exercised its right to co-develop the investigational drug aprocitentan (ACT-132577). Aprocitentan is an investigational hypertension therapy already tested in a Phase II clinical trial….

Reversing trend: US big pharma invests in European biotech companies

The Dutch venture capital fund BioGeneration Ventures yesterday issued a release announcing that it has raised approximately €82m in funding to be invested in medical devices and diagnostics in Germany and Benelux. The main investors include US-based groups Bristol-Myers Squibb…

Janssen invests in Ireland

US-based Janssen – part of Johnson and Johnson group – has announced in a press release a €300m plan to expand its Ringaskiddy plant (Cork, Ireland), which will generate at least 200 new jobs when at full capacity (October 2019)….

Increasing hardship for Teva: Mylan’s generic to Copaxone approved

Teva Pharmaceuticals is experiencing extremely hard times: the FDA today approved for commercialization the generic drug to Copaxone, developed by Mylan. Copaxone is a blockbuster for the treatment of multiple sclerosis, which generated $4.2bn in 2016 ($2bn in H1 2017),…

Pfizer launches firm legal action: sues competitor Johnson & Johnson

US-based pharmaceutical giant Pfizer has brought a lawsuit against its competitor Johnson & Johnson for market disturbance and violation of antitrust laws. Specifically, Pfizer has claimed that, after it launched Inflectra, the biosimilar to Remicade, J&J started proposing to healthcare…

Xarelto significantly reduces major cardiovascular events

Results from the Phase III COMPASS study found that Xarelto (rivaroxaban) 2.5 mg twice daily, plus aspirin 100 mg once daily, significantly reduced the risk of major cardiovascular events: the rate of CV death, heart attack or stroke decreased by…

The strategy to defend blockbusters from biosimilars

Merck and Samsung Bioepis yesterday started selling in the US their biosimilar to Johnson & Johnson’s blockbuster Remicade, with sales of $21bn in 2016. This is the second biosimilar to Remicade: the first was launched in 2016 at a price…

Large-scale clinical trial announced for new JnJ’s AIDS vaccine

It was announced at the International Aids Society Conference, being held in Paris these days, that a large-scale clinical trial designed to assess in Africa the new “Ad26 mosaic” AIDS vaccine, co-developed by Johnson & Johnson and the US National…

Big Pharma increasingly invests in Chinese market

Big Pharma is investing billions of dollars in therapies addressing widespread diseases in China. The country, indeed, has potential to become the first big pharma market in the world and already accounts for 8% of the global sales generated by…

Johnson & Johnson acquired US-based Sentio

Johnson & Johnson acquired US-based Sentio through its subsidiary DePuy Synthes. The parties did not provide the financial details of the transaction. Sentio develops and markets medical devices providing information on spinal nerve location by using adhesive sensors that are…

Actelion Jobs guaranteed

Johnson & Johnson’s managers confirmed the company won’t cut any job in newly-acquired Actelion following the $30bn takeover carried out by the US-based giant. Specifically, JnJ is planning to strengthen its presence in Switzerland, Actelion’s new GM, Jane Griffiths, stated…

Idorsia born from Actelion: a dramatic +37% on first trading day

New pharmaceutical group Idorsia was created yesterday from the acquisition of Actelion by US-based Johnson & Johnson. The new spin-off debuted yesterday in Zurich at the initial price of CHF10, and closed its first day at CHF13.65, totaling a market…

The future of Actelion following acquisition by Johnson & Johnson

Jane Griffiths, the future head of the Actelion unit, acquired by Johnson & Johnson some months ago for $30bn, said in an interview to the WSJ that Actelion will focus on developing and commercializing therapies for pulmonary arterial hypertension (PAH)….

J&J’s first quarter not meeting expectations

Johnson & Johnson announced today, as Wall Street opened, its 2017 first-quarter financial results. Sales increased by 1.6% (vs Q1 2016) to $17.8bn, lower than analysts predicted. Analysts also expected a better performance by the pharmaceuticals business, which generated $8.2bn…